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Recently, He et al. (2008) reported that
persons of sub-Saharan African ancestry,
the majority of whom do not express
DARC on their red blood cells (RBCs),
have a genetic vulnerability to
HIV infection. They estimated
that theDARCnegativepheno-
type conferred by the 46C/C
genotype increases the odds
of HIV infection by 40% and
extrapolated that as much as
11%of theHIVburden inAfrica
may be due to 46C homozy-
gosity. He et al. also reported
that the DARC negative geno-
type was associated with
delayed progression to AIDS-
associated dementia, delayed
CD4+ T cell loss, and longer
survival. DARC expression on
RBC is abolished by the
46T/C transition in the
DARC promoter region that
disrupts the erythrocyte-
specific transcription binding
site (Tournamille et al., 1995).
The46T allele is fixedoutside
of Africa, while the 46C allele
occurs only in Africa and in
persons with African ancestry.
It is hypothesized that the
46C allele arose to near-
fixation in Africa through posi-
tive selection by Plasmodium
vivax—DARC negative individ-
uals lacking the Duffy receptor
used for cell entry by P. vivax
for RBC entry are highly resis-
tant to P. vivax malaria (Horuk
et al., 1993). DARC is a plau-
sible candidate gene for HIV
infection and pathogenesis—it
bindsproinflammatorychemo-
kines, one of which, CCL5
(RANTES), also binds to
CCR5, required by R5 HIV
strains for cell entry (Alkhatib
et al., 1996; Gardner et al.,
2004).CCL5 is anHIV-1 suppression factor
that inhibits replication by both competi-
tively binding to and downregulating
surface expression of CCR5 (Alkhatib
et al., 1997). It has also been reported that
DARC binds HIV to the surface of RBCs
(Lachgar et al., 1998; He et al., 2008). The
DARC negative phenotype is coincident
with the world’s highest HIV prevalence
rates; therefore, the reported influence of
the DARC 46T/C polymorphism on
the HIV epidemic warrants replication and
confirmation.
We determined the extent of population
substructure for 454 HIV-infected (HIV+)
and 425 HIV-uninfected (HIV) persons
enrolled in the ALIVE cohort in Baltimore,
Maryland, all of whom self-reported to be
injecting drug users (Vlahov et al., 1998).
Population substructure is a
major confounding factor,
since DARC 46C is itself a
marker for African ancestry. A
principle components anal-
ysis (PCA) using the EigenSoft
programwith 70 independent,
ancestry-informative markers
revealed that there is minimal
population substructure strat-
ification between the ALIVE
HIV+ and HIV groups (p =
0.2) (Figure S1 and Table S1)
(Kopp et al., 2008; Price
et al., 2006). The first principal
component (the component of
the first eigenvector in the
principle component transfor-
mation) captured the majority
of the variation and,more rele-
vantly, captured the variation
differentiating African from
European ancestry (the eigen-
values of the first 5 compo-
nents were 206, 16, 15, 15,
and 14, respectively).
Genotypes were deter-
mined for DARC 46T/C
using the TaqMan Assays–
on-Demand for rs2814778
(ABI; Foster City, CA). The
genotype frequencies for
46C/C, T/C, and C/C did
not violate Hardy-Weinberg
expectations in either the
HIV+ or HIV groups. Most
importantly, the frequencies
of the 46C/C genotypes in
the HIV+ (66.5%) and HIV
(66.4%) groups were nearly
identical, indicating noassoci-
ation between 46C/C and
HIV acquisition, either in the
unadjusted model (odds ratio
Figure 1. Kaplan-Meier Plots Showing Progression to Two AIDS
Outcomes
Kaplan-Meier plots showing progression to two AIDS outcomes, <200 CD4
T cells/ml and clinical AIDS symptoms (AIDS 1987), for subjects from the
ALIVE cohort for three DARC 46 genotypes: C/C (DARC null phenotype),
red; C/T, green; and T/T, blue. Kaplan-Meier statistics for the log-rank and
Wilcoxon test for a recessive model (DARC 46C/C versus C/T and T/T)
are shown.Cell Host & Microbe 5, May 21, 2009 ª2009 Elsevier Inc. 411
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CorrespondenceTable 1. Impact of DARC 46C/C Conferring the DARC Negative Phenotype on HIV-1 Infection and Disease Progression
DARC 46C/C versus C/T and T/T
Unadjusteda Adjusted for ancestryb
HIV+N (%) HIVN (%) OR, RH (95% CI) P OR, RH (95% CI) P
HIV-1 infection
Genotype n = 454 n = 425
C/C 302 (66.5) 282 (66.4) 0.96 (0.75–1.31) 0.896 1.00 (0.69–1.47) 0.98
T/C 140 (30.8) 131 (30.8)
T/T 12 (2.6) 12 (2.8)
HWE Pc 0.37 0.49
AIDS progressiond
Endpoint N HIV+ (SC)e Events RH (95% CI) P RH (95% CI) P
CD4 200 235 99 0.85 (0.56–1.31) 0.47 0.99 (0.63–1.57) 0.97
AIDS 1987 238 49 1.24 (0.66–2.35) 0.51 1.27 (0.66–2.46) 0.48
aOdds ratio (OR) and 95% confidence interval (CI) were obtained from a conditional logistic regression analysis comparing HIV-1-infected (+) to
HIV-1-uninfected () individuals.
b Adjusted for African ancestry, considering the first eigenvector as a covariate in the analysis.
c Hardy-Weinberg equilibrium test for observed versus expected genotypes.
d Relative hazards (RH) and 95% CI were from Cox proportional hazards model. All models were stratified by age group at seroconversion.
e HIV-1 seroconverters (SC).[OR] = 0.96, p = 0.896) orwith the first prin-
cipal component for each individual
included as a covariate to control for pop-
ulation stratification (OR = 1.00, p = 0.98).
The He et al. group reported an ORz1.5;
given our population size of 879 individ-
uals and an allele frequency of 66%, we
had 75% power to detect an association
of this strength at the 0.05 level. On the
other hand, assuming an actual OR value
of 1.5, as reported by He et al., the proba-
bility of observing OR% 1 in a sample of
our size is 0.01 (calculated assuming
a normal approximation of the log OR),
indicating that our results differ signifi-
cantly from the those reported by He
et al. (2008).
We also tested the role of DARC46C/
C on two HIV outcomes, CD4+ T cell <200
and AIDS-defining conditions (CDC 1987
case definition), using Kaplan-Meier
statistics (Figure 1) and the Cox propor-
tional hazards model (Table 1). To avoid
potential confounding by antiretroviral
therapy, the censoring datewas the earlier
of (1) the date of the last recorded visit or
(2) July 31, 1997 (Celentano et al., 2001).
We did not attempt to replicate the He
et al. finding of favorable outcomes for
AIDS-associated dementia or death,
because reliable data was not available
to us for the former, and we had too few
events to evaluate for AIDS-related death.
As shown in Table 1 and Figure 1, we did
not observe significant associations with412 Cell Host & Microbe 5, May 21, 2009 ª2time to CD4 <200 or AIDS 1987 using
awell-characterized groupof seroconvert-
ers. In the simple Cox model, stratified by
age at seroconversion, the relative hazards
were 0.85 and 1.24 for CD4 <200 and AIDS
1987 (pR 0.47). The results for CD4 <200
and AIDS 1987 were similar after adjusting
for the effects ofHLA,CCR5, andRANTES
genetic factors (relative hazards [RH]=0.84
[95%confidence interval (CI): 0.53–1.31], p
= 0.43, RH = 1.03 [95% CI: 0.53–2.0]) or
after including the eigenvalue scores for
the first principal component as a covariate
to control for population stratification (RH =
0.99, 1.27, pR 0.48, respectively). Inspec-
tionof theKaplan-Meiersurvivalcurvesand
Kaplan-Meier statistics (Figure 1) suggests
no differences in rates of progression to
CD4 <200 or to AIDS 1987 due to46T/
C genotypes. These data do not support
a role for DARC 46T/C in HIV progres-
sion to clinical AIDS.
The results of the He et al. (2008) study
and this onediffermarkedly for association
of HIV infection susceptibility with the
DARC negative phenotype conferred by
46C/C. The ALIVE cohort shows very
little population stratification by the results
of the PCA. Our finding challenges the
conclusion of He et al. (2008) that DARC
46C/C may contribute to the HIV burden
observed in Africa. We suggest that the
infection signal in the He et al. (2008) study
is the result of inadequate correction for
population stratification due to substruc-009 Elsevier Inc.ture between the cases and controls that
led to the false-positive association of the
DARC 46C/C genotype with HIV infec-
tion. He et al. (2008) used 11 informative
markers to determine the probability of
either African or European ancestry and
considered this probability as a covariate
to correct for stratification due to ancestry
substructure between cases and controls;
however, it is thedegreeofAfricanor Euro-
peanancestry that is relevant—particularly
since the DARC 46T/C polymorphism
is among the most informative markers of
African versus non-African ancestry. In
summary, we find no evidence that the
absence ofDARConRBCsdue to abroga-
tion of gene expression by the 46C/C
genotype is associated with greater risk
for HIV infection or delayed progression
to AIDS in African American injecting drug
users either in the unadjusted analysis or
after adjusting for ancestry using the
results of the PCA.
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He et al. recently reported an association
between a single-nucleotide polymor-
phism (SNP) (rs2814778, 46T/C) in the
erythroid-specific promoter region of the
Duffy antigen receptor for chemokine
(DARC) and HIV-1 acquisition and disease
progression inAfricanAmericans (He et al.,
2008). The authors described a higher
frequency of the null homozygous geno-
type (46C/C) in HIV-infected (70%)
versus noninfected individuals (60%).
Based on these findings, they argued that
thenull alleleconfers susceptibility to infec-
tion with HIV-1 and suggested that up to
11% of the HIV-1 burden in sub-Saharan
Africa could be attributed to homozygosity
for the null allele. Oddly, however, these
authors reported that the null genotype
associated with better outcomes among
those who became infected, including
longer survival and, more particularly,
decelerated loss of CD4+ T lymphocytes.
Another report showed an association
between the46C/C genotype and signif-
icantly reduced total white blood cells
(WBCs) in African Americans, explainingREFERENCES
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H. (1998). JAMA 279, 35–40.wild-type (T/T) genotypes on rates of CD4
decline and mean HIV-1 viral loads in
a group of 381 untreated black South
Africans. Since the 46C/C genotype has
previously been associated significantly
with reduced total WBCs (Nalls et al.,
2008), we also determined WBCs in our
cohort in order to verify that our cohort is
sufficiently powered to detect an effect
of the 46 genotype, where 46C/C is
expected to associate with low WBCs as
previously demonstrated.
HIV-1-positive seroprevalent and anti-
retroviral therapy naive subjects (n =
381) were recruited at McCord Hospital
in Durban, South Africa from August
2003 to June 2006 and have been fol-
lowed up to the present time. All subjects
belonged to the local black Zulu/Xhosa
population. Informed consent was ob-
tained from all participating individuals,
and the study was approved by institu-
tional review boards at the University of
KwaZulu Natal, Massachusetts General
Hospital, and the University of Oxford.
Viral load was measured using the Roche
AMPLICOR version 1.5 assay. The mean
viral load of the entire cohort was 4.59
(log10) HIV RNA copies per ml plasma
(interquartile range [IQR], 1.69 [log10]–
6.81 [log10]). CD4
+ T cell, CD8+ T cell, total
lymphocyte, and total white cell counts
were determined by flow cytometry. The
median CD4+ T cell count of all individ-
uals was 350 cells per ml (IQR, 7–1161).
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